This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

CML-Living With A Chronic Disease

WHITE PLAINS, N.Y., April 5, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish-speaking patients with chronic myeloid leukemia (CML). On Wednesday, April 17, from 1:00 to 2:00 PM Eastern Time, international CML expert Dr. Jorge Cortes from The University of Texas MD Anderson Cancer Center will present a free, live telephone/web education program titled CML–Living with a Chronic Disease. This program will be presented simultaneously in Spanish.

Since the advent of targeted therapies, three of which are now approved for the treatment of newly diagnosed chronic phase CML, survival and quality of life for patients with CML has dramatically improved. Recent studies show that more than 90% of newly diagnosed, early stage CML patients can expect to survive long-term. Just as LLS was instrumental in funding the research which led to the development of imatinib (Gleevec ®), LLS is also committed to ensuring that these treatment advances reach all patients. The telephone/web program on April 17 will provide Spanish-speaking patients and caregivers the opportunity to learn about the latest advances in CML treatment and quality of life from one of the leading experts in the field. Dr. Cortes will discuss CML treatment options, as well as the critical importance of treatment adherence and monitoring of treatment response. This program, offered by The Leukemia & Lymphoma Society in collaboration with Abrale and Alianza Latina is supported by grants from Bristol-Myers Squibb and Novartis Oncology. The Leukemia & Lymphoma Society is pleased to offer continuing education credit for nurses and social workers.

To register for the April 17 program CML–Living with a Chronic Disease in Spanish, please visit www.LLS.org/CMLsp.

To register for CML–Living with a Chronic Disease in English, please visit www.LLS.org/programs.

For information on other LLS programs, please visit www.LLS.org or contact an Information Specialist at (800) 955-4572.

About The Leukemia & Lymphoma SocietyThe Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET

Contact: Andrea Greif914.821.8958 andrea.greif@lls.org 

SOURCE The Leukemia & Lymphoma Society

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs